Skip to content

The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots

Open-labelled Study to Validate Home-based Use of a Health and Wellness Kit (The Mitopure Challenge) to Detect Levels of Urolithin A in Dried Blood Spots After Intake of Mitopure (Proprietary Urolithin A)

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04985630
Enrollment
250
Registered
2021-08-02
Start date
2021-08-30
Completion date
2026-08-31
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Healthy Aging, Healthy Diet

Brief summary

Open labelled, virtual home based study to assess the test repeatability and the failure/rejection rate of the samples collected at home by participants.

Interventions

DIETARY_SUPPLEMENTMitopure

Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)

DIETARY_SUPPLEMENTPomegranate Juice

100% Pomegranate juice

Sponsors

Amazentis SA
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

1. Males and females 18 to 80 years of age; 2. Is in general good health, as determined by the research team; 3. Willingness to consume the investigation product, complete questionnaires and to complete the study; 4. Have given voluntary, electronic, informed consent to be a participant in the study.

Exclusion criteria

1. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial; 2. Volunteers who plan to donate blood during the study or within 30 days of completing the study; 3. Subject has a known allergy to the test material's active or inactive ingredients; 4. Subjects with unstable medical conditions; 5. Participation in a clinical research trial within 30 days prior to randomization; 6. Allergy or sensitivity to study ingredients; 7. Individuals who are cognitively impaired and/or who are unable to give informed consent; 8. Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject; 9. Has taken antibiotics within the previous 30 days.

Design outcomes

Primary

MeasureTime frameDescription
Failure/rejection rate (% of the samples) collected at home by participants.4 weeksAcceptability target goal is to hit 80% of analyzed samples

Secondary

MeasureTime frame
Sensitivity and specificity (% of the samples) of the analytical method developed to test Urolithin A in dry blood spots.4 weeks
Fold change increase in the levels of UA-Glucuronide (in ng/mL) in the dried blood spots provided in the kit before and after the challenge4 weeks
Validation of a health questionnaire on participants health status4 weeks

Countries

United States

Contacts

Primary ContactJulie Faitg, PhD
jfaitg@amazentis.com+41215521272

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026